Improved detection of microbiological pathogens: role of partner and non-governmental organizations.
Anti-Bacterial Agents
/ pharmacology
Bacteria
/ drug effects
Bacterial Infections
/ diagnosis
Blood
/ microbiology
Cerebrospinal Fluid
/ microbiology
Drug Resistance, Bacterial
/ drug effects
Feces
/ microbiology
Ghana
Humans
Laboratories
Microbial Sensitivity Tests
Organizations
Retrospective Studies
Seasons
Urine
/ microbiology
Detection
Non-governmental organization
Pathogens
Public health laboratories
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
25 Mar 2021
25 Mar 2021
Historique:
received:
23
08
2020
accepted:
18
03
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
7
4
2021
Statut:
epublish
Résumé
Proper detection of disease-causing organisms is very critical in controlling the course of outbreaks and avoiding large-scale epidemics. Nonetheless, availability of resources to address these gaps have been difficult due to limited funding. This report sought to highlight the importance of in-country partners and non-governmental organizations in improving detection of microbiological organisms in Ghanaian Public Health Laboratories (PHLs). This study was conducted between June, 2018 to August, 2019. U. S CDC engaged the Centre for Health Systems Strengthening (CfHSS) through the Association of Public Health Laboratories to design and implement strategies for strengthening three PHLs in Ghana. An assessment of the three PHLs was done using the WHO/CDS/CSR/ISR/2001.2 assessment tool. Based on findings from the assessments, partner organizations (CfHSS/APHL/CDC) serviced and procured microbiological equipment, laboratory reagents and logistics. CfHSS provided in-house mentoring and consultants to assist with capacity building in detection of epidemic-prone infectious pathogens by performing microbiological cultures and antimicrobial susceptibility tests. A total of 3902 samples were tested: blood (1107), urine (1742), stool (249) and cerebrospinal fluid (CSF) (804). All-inclusive, 593 pathogenic bacteria were isolated from blood cultures (70; 11.8%); urine cultures (356; 60%); stool cultures (19; 3.2%) and from CSF samples (148; 25%). The most predominant pathogens isolated from blood, urine and stool were Staphylococcus aureus (22/70; 31%), Escherichia coli (153/356; 43%) and Vibrio parahaemolyticus (5/19; 26.3%), respectively. In CSF samples, Streptococcus pneumoniae was the most frequent pathogen detected (80/148; 54.1%). New bacterial species such as Pastuerella pneumotropica, Klebsiella oxytoca, Vibrio parahaemolyticus, and Halfnia alvei were also identified with the aid of Analytical Profile Index (API) kits that were introduced as part of this implementation. Streptococcus pneumoniae and Neisseria meningitidis detections in CSF were highest during the hot dry season. Antimicrobial susceptibility test revealed high rate of S. aureus, K. pneumoniae and E. coli resistance to gentamicin (35-55%). In urine, E. coli was highly resistant to ciprofloxacin (39.2%) and ampicillin (34%). Detection of epidemic-prone pathogens can be greatly improved if laboratory capacity is strengthened. In-country partner organizations are encouraged to support this move to ensure accurate diagnosis of diseases and correct antimicrobial testing.
Sections du résumé
BACKGROUND
BACKGROUND
Proper detection of disease-causing organisms is very critical in controlling the course of outbreaks and avoiding large-scale epidemics. Nonetheless, availability of resources to address these gaps have been difficult due to limited funding. This report sought to highlight the importance of in-country partners and non-governmental organizations in improving detection of microbiological organisms in Ghanaian Public Health Laboratories (PHLs).
METHODS/CONTEXT
UNASSIGNED
This study was conducted between June, 2018 to August, 2019. U. S CDC engaged the Centre for Health Systems Strengthening (CfHSS) through the Association of Public Health Laboratories to design and implement strategies for strengthening three PHLs in Ghana. An assessment of the three PHLs was done using the WHO/CDS/CSR/ISR/2001.2 assessment tool. Based on findings from the assessments, partner organizations (CfHSS/APHL/CDC) serviced and procured microbiological equipment, laboratory reagents and logistics. CfHSS provided in-house mentoring and consultants to assist with capacity building in detection of epidemic-prone infectious pathogens by performing microbiological cultures and antimicrobial susceptibility tests.
RESULTS
RESULTS
A total of 3902 samples were tested: blood (1107), urine (1742), stool (249) and cerebrospinal fluid (CSF) (804). All-inclusive, 593 pathogenic bacteria were isolated from blood cultures (70; 11.8%); urine cultures (356; 60%); stool cultures (19; 3.2%) and from CSF samples (148; 25%). The most predominant pathogens isolated from blood, urine and stool were Staphylococcus aureus (22/70; 31%), Escherichia coli (153/356; 43%) and Vibrio parahaemolyticus (5/19; 26.3%), respectively. In CSF samples, Streptococcus pneumoniae was the most frequent pathogen detected (80/148; 54.1%). New bacterial species such as Pastuerella pneumotropica, Klebsiella oxytoca, Vibrio parahaemolyticus, and Halfnia alvei were also identified with the aid of Analytical Profile Index (API) kits that were introduced as part of this implementation. Streptococcus pneumoniae and Neisseria meningitidis detections in CSF were highest during the hot dry season. Antimicrobial susceptibility test revealed high rate of S. aureus, K. pneumoniae and E. coli resistance to gentamicin (35-55%). In urine, E. coli was highly resistant to ciprofloxacin (39.2%) and ampicillin (34%).
CONCLUSION
CONCLUSIONS
Detection of epidemic-prone pathogens can be greatly improved if laboratory capacity is strengthened. In-country partner organizations are encouraged to support this move to ensure accurate diagnosis of diseases and correct antimicrobial testing.
Identifiants
pubmed: 33765944
doi: 10.1186/s12879-021-05999-8
pii: 10.1186/s12879-021-05999-8
pmc: PMC7993523
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
303Subventions
Organisme : CDC HHS
ID : NA
Pays : United States
Références
Clin Microbiol Rev. 2014 Oct;27(4):783-822
pubmed: 25278575
N Am J Med Sci. 2011 Feb;3(2):75-7
pubmed: 22540069
Sultan Qaboos Univ Med J. 2013 Aug;13(3):359-67
pubmed: 23984019
Can J Infect Dis. 2001 Sep;12(5):289-92
pubmed: 18159352
Clin Infect Dis. 2005 Jan 1;40(1):17-25
pubmed: 15614687
Front Public Health. 2017 Jul 12;5:148
pubmed: 28752086
Infect Control Hosp Epidemiol. 2012 Jun;33(6):594-601
pubmed: 22561715
BMC Pediatr. 2015 Apr 02;15:33
pubmed: 25884449
Sci Am. 1998 Mar;278(3):46-53
pubmed: 9487702
Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
BMC Public Health. 2018 Jun 22;18(1):781
pubmed: 29929517
J Infect Dis. 2000 Oct;182(4):1177-82
pubmed: 10979915
MMWR Morb Mortal Wkly Rep. 2017 Aug 04;66(30):806-810
pubmed: 28771457
Am J Trop Med Hyg. 1977 Jul;26(4):748-55
pubmed: 889015
Ther Adv Urol. 2019 May 02;11:1756287219832172
pubmed: 31105774
Korean J Intern Med. 2014 Jan;29(1):27-30
pubmed: 24574830
Best Pract Res Clin Obstet Gynaecol. 2005 Dec;19(6):861-73
pubmed: 16298166
PLoS Med. 2005 Jan;2(1):e6
pubmed: 15696216
Int J Environ Res Public Health. 2014 Jul 07;11(7):6923-39
pubmed: 25003550
Curr Opin Infect Dis. 2010 Oct;23(5):409-14
pubmed: 20736739
Curr Opin Otolaryngol Head Neck Surg. 2007 Oct;15(5):352-7
pubmed: 17823553
Microb Drug Resist. 2011 Jun;17(2):267-73
pubmed: 21388296
Trop Med Int Health. 2008 Dec;13(12):1543-52
pubmed: 18983283
Hemodial Int. 2007 Jan;11(1):72-5
pubmed: 17257359
Cureus. 2017 Jun 28;9(6):e1403
pubmed: 28852600
N Engl J Med. 2005 Jan 6;352(1):39-47
pubmed: 15635111
Clin Infect Dis. 2009 May 15;48 Suppl 4:S231-7
pubmed: 19374578
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3170-3
pubmed: 26926640
Clin Infect Dis. 2006 Feb 1;42(3):377-82
pubmed: 16392084
P T. 2015 Apr;40(4):277-83
pubmed: 25859123
Global Health. 2020 Jul 25;16(1):67
pubmed: 32711553
Front Microbiol. 2014 Dec 11;5:705
pubmed: 25566219
JAMA. 2005 Jun 22;293(24):3012-21
pubmed: 15972563